Currently, there is an ongoing patient recruitment by EcoNugenics for a Phase III clinical trial pointing at the effects of orally administered PectaSol-C for improving PSA kinetics in men with biochemical relapsed prostate cancer and serial increasing PSA (NCT: NCT01681823) (120). This evidence concerns the gene KLK3 and prostate cancer.